Compare PepsiCo, Inc. (PEP) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Zoetis Inc — how do they compare? PepsiCo, Inc. trades at $125.97 (market cap $174.89B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: PepsiCo, Inc. is far larger — about 5.8× Zoetis Inc's market cap, and PepsiCo, Inc. pays the higher dividend (4.61%). Which is the better fit depends on your goals — on Pluang, investors hold PepsiCo, Inc. for 107 Days and Zoetis Inc for 70 Days on average.
| PEP | ZTS | |
|---|---|---|
Market Cap | $174.89B | $30.20B |
Volume | 23,968,864 | 6,175,327 |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $147.53 |
52-Week Low | $123.64 | $69.09 |
Typical Hold Time | 107 Days | 70 Days |
Enterprise Value | $215.61B | $37.76B |
Dividend Yield | 4.61% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $128.88, up 4.24% today, with a bearish technical signal but strong fundamentals including a 16.14 P/E ratio and 51.59% ROE. Recent quarters show consistent earnings beats, with Q3 2026 EPS of $2.34 exceeding expectations. The company maintains robust cash flow, with 2025 operating cash flow of $12.09 billion, and announced a $1.48 dividend for H2-2026. News highlights price cuts on snacks like Doritos to address consumer pushback on high prices.
The outlook is mixed: analyst consensus targets $146.77 (14% upside) with a 'Hold' bias, but technicals suggest near-term pressure. Risks include competitive pricing pressures and debt levels, while opportunities lie in margin recovery and North American turnaround efforts. The stock offers value with a reasonable valuation and dividend yield, but requires monitoring of volume trends post-price adjustments.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
